15. 封入体筋炎 Inclusion body myositis Clinical trials / Disease details

臨床試験数 : 42 / 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-001411-12-DK (EUCTR)	10/11/2015	11/09/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.1;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Australia;Denmark;Netherlands;Japan;Italy;United Kingdom;Switzerland
2	EUCTR2015-001411-12-BE (EUCTR)	09/11/2015	12/10/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland
3	EUCTR2015-001411-12-GB (EUCTR)	04/11/2015	21/09/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Belgium;Denmark;Australia;Netherlands;Japan;Italy;Switzerland;United Kingdom
4	EUCTR2015-001411-12-FR (EUCTR)	04/11/2015	05/08/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	United States;France;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland
5	NCT02573467 (ClinicalTrials.gov)	November 2, 2015	9/7/2015	An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With ...	Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tol ...	Sporadic Inclusion Body Myositis	Drug: Bimagrumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	36 Years	N/A	All	211	Phase 3	United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom
6	JPRN-JapicCTI-153078	01/11/2015	25/11/2015	Extension Study of the Long-term Efficacy and Safety of BYM338 in Patients With Sporadic Inclusion B ...	Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tol ...	Sporadic Inclusion Body Myositis	Intervention name : BYM338 INN of the intervention : Bimagrumab Dosage And administration of the inter ...	Novartis Pharma K.K.	NULL		36		BOTH	240	Phase 2-3	NULL
7	EUCTR2015-001411-12-NL (EUCTR)	22/10/2015	17/08/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 19.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland
8	EUCTR2015-001411-12-IT (EUCTR)	14/10/2015	27/02/2018	Extension study to evaluate the long-term efficacy, safety and tolerabilityof BYM338 in patients wit ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the longtermefficacy, safety and toler ...	Sporadic Inclusion Body Myositis MedDRA version: 20.0;Level: PT;Classification code 10066407;Term: I ...	Product Name: Bimagrumab Product Code: BYM338	NOVARTIS FARMA S.P.A.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Denmark;Australia;Netherlands;Japan;United Kingdom;Switzerland;Italy
9	NCT02250443 (ClinicalTrials.gov)	March 11, 2014	20/3/2014	Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body ...	An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sp ...	Sporadic Inclusion Body Myositis (sIBM)	Drug: BYM338 (Bimagrumab)	Novartis Pharmaceuticals	NULL	Completed	40 Years	75 Years	All	10	Phase 2/Phase 3	United States
10	EUCTR2013-000705-23-IT (EUCTR)	09/02/2014	12/12/2013	Study of efficacy and safety of BYM338 in sporadic inclusion body myositispatients	A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, ...	Sporadic Inclusion Body Myositis MedDRA version: 14.1;Level: PT;Classification code 10066407;Term: I ...	Product Name: BYM338 Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Farma SpA	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	Netherlands;France;United States;Belgium;Poland;Denmark;Australia;Germany;Japan;United Kingdom;Switz ...

First Previous1 2Next Last